Trial Profile
A retrospective, multicenter study evaluating efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jan 2018
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Jan 2018 New trial record
- 01 Dec 2017 Results published in the Hepatology Research